Resumes
Resumes
Akhouri Sinha Phones & Addresses
-
3254 48Th Ave S, Minneapolis, MN 55406 (612) 724-4871
-
New Orleans, LA
Publications
Us Patents
Targeting Of Organs By Immunoconjugates
View pageUS Patent:
20020001588, Jan 3, 2002
Filed:
Aug 15, 2001
Appl. No.:
09/930508
Inventors:
Akhouri Sinha - Minneapolis MN, US
International Classification:
A61K039/395
C07K016/46
C07K016/46
US Classification:
424/178100, 530/391100
Abstract:
Bioactive materials, e.g. therapeutic agents for treating a condition that afflicts a patient, are delivered to the afflicted organ in a site-specific manner by coupling the bioactive agent to an antibody or fragment or derivative thereof that recognizes a substance unique to that organ. For example, therapeutic agents for treating conditions of the prostate gland such as adenocarcinoma of the prostate, benign prostatic hypertrophy and prostatitis can be delivered to the prostate by coupling the thereapeutic agent to an antibody against a substance secreted by the prostate, e.g. prostatic specific antigen or prostatic acid phosphatase.
Method And Materials For Assessing Cancer Aggressiveness
View pageUS Patent:
20040038240, Feb 26, 2004
Filed:
Jun 12, 2003
Appl. No.:
10/332628
Inventors:
Akhouri Sinha - Minneapolis MN, US
Michael Wilson - St. Paul MN, US
Barry Quast - Minneapolis MN, US
Michael Wilson - St. Paul MN, US
Barry Quast - Minneapolis MN, US
International Classification:
C12Q001/68
C12P019/34
C12P019/34
US Classification:
435/006000, 435/091200
Abstract:
The invention involves the predicting the aggressiveness of cancer. Specifically, the invention provides methods and materials for evaluating the ratio of CB to stefin A such that the aggressiveness of cancer can be predicted.
Targeting Of Organs By Immunoconjugates
View pageUS Patent:
6379669, Apr 30, 2002
Filed:
Aug 2, 1996
Appl. No.:
08/691565
Inventors:
Akhouri A. Sinha - Minneapolis MN, 55406
International Classification:
A61K 39395
US Classification:
4241781, 4241791, 4241811, 4241831
Abstract:
Bioactive materials, e. g. therapeutic agents for treating a condition that afflicts a patient, are delivered to the afflicted organ in a site-specific manner by coupling the bioactive agent to an antibody or fragment or derivative thereof that recognizes a substance unique to that organ. For example, therapeutic agents for treating conditions of the prostate gland such as adenocarcinoma of the prostate, benign prostatic hypertrophy and prostatitis can be delivered to the prostate by coupling the thereapeutic agent to an antibody against a substance secreted by the prostate, e. g. prostatic specific antigen or prostatic acid phosphatase.